Literature DB >> 21911849

Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study.

Knut-Arne Wensaas1, Nina Langeland, Kurt Hanevik, Kristine Mørch, Geir Egil Eide, Guri Rortveit.   

Abstract

BACKGROUND: Giardia lamblia is a common cause of gastroenteritis worldwide, but there is limited knowledge about the long-term complications.
OBJECTIVE: To estimate the relative risk of irritable bowel syndrome (IBS) and chronic fatigue 3 years after acute giardiasis.
DESIGN: Controlled historic cohort study with 3 years' follow-up. Data collected by mailed questionnaire.
SETTING: Waterborne outbreak of giardiasis in the city of Bergen, Norway. PARTICIPANTS: 817 patients exposed to Giardia lamblia infection verified by detection of cysts in stool samples and 1128 matched controls. MAIN OUTCOME MEASURES: IBS and chronic fatigue.
RESULTS: The prevalence of IBS in the exposed group was 46.1%, compared with 14.0% in the control group, and the adjusted RR=3.4 (95% CI 2.9 to 3.8). Chronic fatigue was reported by 46.1% of the exposed group and 12.0% of the controls, the adjusted RR was 4.0 (95% CI 3.5 to 4.5). IBS and chronic fatigue were associated and the RR for the exposed group of having a combination of the two outcomes was 6.8 (95% CI 5.3 to 8.5). The RR was also increased for having just one of the two syndromes, 1.8 for IBS (95% CI 1.4 to 2.3) and 2.2 for chronic fatigue (95% CI 1.7 to 2.8).
CONCLUSIONS: Infection with Giardia lamblia in a non-endemic area was associated with a high prevalence of IBS and chronic fatigue 3 years after acute illness, and the risk was significantly higher than in the control group. This shows that the potential consequences of giardiasis are more serious than previously known. Further studies are needed, especially in areas where giardiasis is endemic.

Entities:  

Mesh:

Year:  2011        PMID: 21911849     DOI: 10.1136/gutjnl-2011-300220

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  62 in total

1.  Infection: Giardia lamblia is associated with an increased risk of both IBS and chronic fatigue that persists for at least 3 years.

Authors:  Natalie J Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-11       Impact factor: 46.802

Review 2.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 3.  Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis.

Authors:  Fabiane Klem; Akhilesh Wadhwa; Larry J Prokop; Wendy J Sundt; Gianrico Farrugia; Michael Camilleri; Siddharth Singh; Madhusudan Grover
Journal:  Gastroenterology       Date:  2017-01-06       Impact factor: 22.682

Review 4.  Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?

Authors:  S E Kim; L Chang
Journal:  Neurogastroenterol Motil       Date:  2012-08-02       Impact factor: 3.598

5.  Infectious disease: Something in the water.

Authors:  Sujata Gupta
Journal:  Nature       Date:  2016-05-19       Impact factor: 49.962

Review 6.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

7.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

Review 8.  Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection.

Authors:  Jennifer K Beatty; Amol Bhargava; Andre G Buret
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

9.  A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia.

Authors:  Noa Tejman-Yarden; Yukiko Miyamoto; David Leitsch; Jennifer Santini; Anjan Debnath; Jiri Gut; James H McKerrow; Sharon L Reed; Lars Eckmann
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

10.  Treatment of giardiasis: current status and future directions.

Authors:  Richard R Watkins; Lars Eckmann
Journal:  Curr Infect Dis Rep       Date:  2014-02       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.